Drug Database
ER

erythropoietin (Epodion / DWP413 / Eposis)

✓ Approved

Daewoong Pharmaceutical · EPOR · 重组蛋白

什么是 erythropoietin?

erythropoietin 是一种重组蛋白,由Daewoong Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名Epodion, DWP413, Eposis
公司Daewoong Pharmaceutical
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

erythropoietin 作用于 1 个分子靶点:

EPORerythropoietin receptor (EPO-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

erythropoietin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-19

Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report.

Jiang Sufang S, Zhou Yumei Y, Xie Yunhan Y, Song Shaowei S et al.

Anemia is a prevalent complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Recombinant human erythropoietin (rhEPO) is widely administered to patients both on and off dialysis to manage this anemia. However, despite an initial favorable therapeutic response, a sudden and unexplained decline in hemoglobin (Hb) levels often prompts the need for further diagnostic evaluation. In this context, we report a clinical case involving a 48-year-old male patient who had been undergoing hemodialysis (HD) for two years. During the course of his rhEPO treatment regimen, he may have developed pure red cell aplasia (PRCA), a rare but serious adverse reaction. Upon recognition of this complication, the administration of rhEPO was promptly discontinued, and the patient was initiated on roxadustat therapy. Following nine months of continuous roxadustat treatment, the patient experienced a significant and sustained increase in his Hb levels. This clinical outcome underscores the importance of prompt diagnosis and intervention in cases of suspected erythropoietin (EPO)-induced PRCA. Furthermore, our findings suggest that roxadustat may serve as a viable and effective therapeutic option for patients with suspected EPO-induced PRCA, potentially obviating the need for immunosuppressive therapy and its associated risks.

PMID 43052388
阅读全文 →
PubMedCureus2026-11-18

Prevalence and Correlates of Depression in Patients With Chronic Kidney Disease Undergoing Maintenance Hemodialysis at a Tertiary Care Center in Kerala.

Abdul Rezak Parayil Abeer A, Punnoose Varghese V, Alex Sandeep S

Introduction Chronic kidney disease (CKD) is a disabling illness with significant physical, psychological and social consequences. Patients undergoing hemodialysis are at increased risk of developing depressive disorders. Biochemical derangements associated with kidney disease, compounded by the psychological burden of physical and social disability, are established contributory factors. Data on the prevalence and correlates of depression in CKD patients in Kerala remain scarce. Identification of depression in early stages is important in CKD patients as it is a significant predictor of disease progression, hemodialysis initiation, hospitalization, and death. This study aimed to determine the prevalence of depression in CKD patients on maintenance hemodialysis and to identify any sociodemographic, clinical, or biochemical correlates. Materials and methods A cross-sectional descriptive study was conducted in the Department of Nephrology, Government T.D. Medical College, Alappuzha, Kerala, over a period of one year. A total of 120 participants were enrolled in the study using consecutive sampling. Sociodemographic, clinical, and biochemical data were collected using a specially designed proforma. Depression was clinically diagnosed by a psychiatrist using ICD-10 Diagnostic Criteria for Research (ICD-10-DCR). The severity of the depressive episode was assessed using the Beck Depression Inventory-II (BDI-II). Data were analyzed using appropriate statistical tests. Multiple linear and binary logistic regression analyses were performed to identify the variables independently associated with the diagnosis of depression and depressive symptom severity. Results The prevalence of depression was 42.5% (51 of 120 patients; 95% CI 34.0-51.4%). Among depressed participants, severity was mild in 18 (35.3%), moderate in 26 (51.0%), and severe in 7 (13.7%). The mean BDI-II score for the whole sample was 17.25 ± 6.59. In univariate analysis, depression was significantly associated with socioeconomic status, low body mass index, shorter duration of dialysis, erythropoietin therapy, hyponatremia, hypocalcemia, lower hemoglobin, lower serum albumin, and higher high-sensitivity C-reactive protein (hs-CRP). In multiple linear regression, lower hemoglobin (β = -0.267, p = 0.002) and lower serum sodium (β = -0.236, p = 0.006) remained independently associated with a higher BDI-II score, with the model accounting for 30.8% of the variance (adjusted R² = 0.271, F = 8.367, p < 0.001). In binary logistic regression, hemoglobin was the only variable independently associated with depression status, with each 1 g/dL lower hemoglobin corresponding to 8.20-fold higher odds of depression (95% CI 2.56-26.32, p < 0.001); hyponatremia fell just short of conventional significance (adjusted OR 2.55, 95% CI 1.00-6.54, p = 0.051). Conclusion The high prevalence of depression among CKD patients undergoing maintenance hemodialysis suggests that clinicians should actively screen for depressive symptoms in these patients, especially those with the identified biochemical risk factors, to enable early identification and improve quality of life.

PMID 43048631
阅读全文 →
PubMedThe Journal of rheumatology2026-11-16

An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report.

Ouamer Ilham I, Belkhadir Samia S, Berkchi Moulay Jihad MJ, Achemlal Lahsen L

PMID 43035231
阅读全文 →
PubMedThe American journal of clinical nutrition2026-11-16

Reduced Erythropoietic Signalling may be responsible for anemia without iron deficiency among Indian Pregnant Women: findings from a cross-sectional study.

Palika Ravindranadh R, Chilumula Monica M, Dasi Teena T, Banjara Santosh Kumar SK et al.

A substantial proportion of anemia is not associated with iron deficiency (ID), particularly in India. However, the aetiology of anemia without ID remains elusive. To compare erythropoietic activity markers (erythropoietin, erythroferrone), micronutrient profiles, and inflammatory markers across four mutually exclusive groups of anemia and iron deficiency (ID) status: anemia with ID, anemia without ID, no-anemia with ID, and no-anemia and no-ID, to identify the factors associated with anemia without ID. In this cross-sectional study, pregnant women in their third trimester (n=687) were screened for complete blood count including hemoglobin, plasma ferritin (PF), soluble transferrin-receptor (sTfR), high-sensitive C-reactive protein (hsCRP) and Alpha-1-Acid Glycoprotein (AGP), vitamins B12, A, D and red blood cell-folate and in a sub-sample hepcidin, erythropoietin (EPO) and erythroferrone (EFRE) levels were measured. Anemia was defined when Hemoglobin <11g/dL and ID was defined when inflammation adjusted PF levels <20μg/L. The prevalence of anemia with ID, anemia without ID, no-anemia with ID and no-anemia and no ID were 26%, 21%, 11%, 42%, respectively. The anemia with ID group exhibited significantly lower mean Hb (9.32g/dL; 95% CI: 9.1, 9.5 Vs 10.08g/dL 95%CI: 9.9, 10.2), EFRE (0.55ng/mL, 95%CI: 0.5, 0.7 Vs 0.19ng/mL 95%CI: 0.1, 0.3) and higher median EPO (28.18mIU/mL; IQRs: 22.7, 41.0 Vs 22.00mIU/mL; IQRs: 20.8, 24.5) compared to anemia without ID group. Furthermore, despite lower hemoglobin, median EPO in anemia without ID was comparable to non-anemic groups. Micronutrient or Inflammatory markers were either similar or did not show consistent trends across the four groups. Further, hemoglobin levels showed significant negative correlation with EPO (r=-0.55, p<0.001) in anemia with ID group, but not in anemia without ID group (r=0.11, p=0.438). Our study findings suggest that reduced erythropoietic signalling may underly anemia without ID, which is not explained by inflammation or micronutrient deficiencies. Thus, diagnosing ID is vital for effective iron treatment.

PMID 43039146
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study.

Gadassi Noa N, Goldstein Sivahn S, Wulkan Michal M, Grinblatt Eynit E et al.

Objectives: To compare the effects of two different erythropoiesis-stimulating agents [ESAs] and no treatment on the number of blood transfusions and hematocrit [Hct] level. Methods: A retrospective study. Kaplan Medical Center provided data on ESA-treated infants, comparing erythropoietin [EPO] given per protocol until 2018 and darbepoetin [DPO] given from 2018 onwards. Meir Medical Center's data formed the control group. Data regarding ESA treatment were extracted from a computerized prospective database. A comparison of Hct levels at birth, 14 days of age, 1 month and before discharge and number of blood transfusions received during hospitalization was performed. Mean and standard deviation or median and interquartile range were used for continuous variables and frequency tables for categorical variables. Results: In total, 248 premature infants born between 2016 and 2021 under 1250 g, who survived beyond two weeks of age, were included. No significant differences were found between the EPO and DPO groups in terms of number of blood transfusions or Hct values. The control group received more blood transfusions after two weeks of age [0.8 ± 1.5 vs. 0.5 ± 1.2, p-value = 0.02]. In the treated group, higher Hct values were observed at one month of age [29.9 ± 4.2 vs. 37.9 ± 5.3, p-value < 0.01] and at discharge [29.7 ± 3.8 vs. 34.1 ± 4.6, p-value < 0.01] compared to the control group. Conclusions: ESA treatment was associated with higher hematocrit levels, and no significant differences in efficacy were found between EPO and DPO.

PMID 43030394
阅读全文 →
PubMedAdvanced drug delivery reviews2026-11-14

Toward precision nanomedicine via artificial intelligence guided design and prediction.

Choi Jaehyun J, Xu Enzhen E, Park Sihyun S, Woo Minji M et al.

Artificial intelligence (AI) is advancing nanomedicine development by linking formulation variables and biological context with delivery, therapeutic efficacy, and safety. This review examines AI assisted formulation design, centralized formulation databases, prediction of nanoparticle self assembly, and models of cell and tissue selective delivery, biodistribution, and therapeutic outcomes. Recent advances in predicting nanotoxicity and nanoparticle induced immune responses further emphasize the importance of incorporating safety endpoints into nanomedicine optimization. Beyond nanocarrier engineering, foundation models and multimodal analyses of single-cell and spatial data are expanding biological discovery by characterizing disease associated cellular states, prioritizing therapeutic targets, and predicting treatment responses. Computational approaches also support the design of therapeutic RNA, peptides, proteins, and programmable protein nanomaterials. For example, mRNA sequences generated by GEMORNA and delivered via lipid nanoparticles increased erythropoietin expression in mice by up to 15-fold compared with a benchmark sequence. Integration of biological discovery with biomolecular and nanocarrier design may inform therapeutic cargo selection, targeting strategies, and functional nanomaterial development. AI may connect patient specific biological characteristics with predictions of nanomedicine delivery and therapeutic response to support patient stratification and individualized treatment selection. Integration of histological, imaging, molecular, and longitudinal data may enable treatment strategies to be adapted to differences in tissue characteristics, disease state, and therapeutic response. Emerging approaches based on digital twins and adaptive treatment control may extend the framework toward individualized dosing and dynamic treatment optimization. Major challenges include data heterogeneity, limited model generalizability, and the need for experimental and prospective validation. Progress toward precision therapy will require integrated frameworks that jointly consider delivery, efficacy, selectivity, and safety while clearly distinguishing demonstrated applications from future opportunities.

PMID 43025814
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多erythropoietin